Research ExplorerPublicationsMonoklonale Gammopathie unklarer Signifikanz – ein häufiger ...

Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund

Standard

Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund : Woran ist zu denken? Was ist zu tun? / Schieferdecker, Aneta; Binder, Mascha; Weisel, Katja; Bokemeyer, Carsten.

In: DEUT MED WOCHENSCHR, Vol. 144, No. 14, 07.2019, p. 982-989.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Schieferdecker, A, Binder, M, Weisel, K & Bokemeyer, C 2019, 'Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun?', DEUT MED WOCHENSCHR, vol. 144, no. 14, pp. 982-989. https://doi.org/10.1055/a-0832-3393

APA

Schieferdecker, A., Binder, M., Weisel, K., & Bokemeyer, C. (2019). Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun? DEUT MED WOCHENSCHR, 144(14), 982-989. https://doi.org/10.1055/a-0832-3393

Vancouver

Schieferdecker A, Binder M, Weisel K, Bokemeyer C. Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun? DEUT MED WOCHENSCHR. 2019 Jul;144(14):982-989. https://doi.org/10.1055/a-0832-3393

Bibtex

@article{8430f048af114e3d9d703e37f0e4870e,
title = "Monoklonale Gammopathie unklarer Signifikanz – ein h{\"a}ufiger Nebenbefund: Woran ist zu denken? Was ist zu tun?",
abstract = "Monoclonal gammopathy of unclear significance (MGUS) is detected at high frequency in a variety of disciplines as an incidental finding. MGUS can be associated with non-malignant diseases, but it also can be a precursor of malignant lymphoproliferative disorders (multiple myeloma, Waldenstroem's disease, other non-Hodgkin's lymphoma, light chain (AL) - amyloidosis). However, many of these patients remain asymptomatic throughout their lives. Screening is performed by serum protein electrophoresis, immunofixation and determination of quantitative immunoglobulins and free light chains in serum. Currently, general population screening is not recommended. There are three subtypes with different rates and types of progression: IgM-MGUS, non-IgM-MGUS, and light-chain MGUS. The scope of further diagnostics and follow-up is based on the clinical findings and risk stratification (monoclonal protein in serum < or ≥ 15 g/l and normal or abnormal free light chain ratio in serum). If paraprotein-associated disease is detected, gammopathy is of clinical significance and should not be referred to as MGUS.",
keywords = "Disease Progression, Humans, Incidental Findings, Monoclonal Gammopathy of Undetermined Significance/diagnosis",
author = "Aneta Schieferdecker and Mascha Binder and Katja Weisel and Carsten Bokemeyer",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2019",
month = jul,
doi = "10.1055/a-0832-3393",
language = "Deutsch",
volume = "144",
pages = "982--989",
journal = "DEUT MED WOCHENSCHR",
issn = "0012-0472",
publisher = "Georg Thieme Verlag KG",
number = "14",

}

RIS

TY - JOUR

T1 - Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund

T2 - Woran ist zu denken? Was ist zu tun?

AU - Schieferdecker, Aneta

AU - Binder, Mascha

AU - Weisel, Katja

AU - Bokemeyer, Carsten

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2019/7

Y1 - 2019/7

N2 - Monoclonal gammopathy of unclear significance (MGUS) is detected at high frequency in a variety of disciplines as an incidental finding. MGUS can be associated with non-malignant diseases, but it also can be a precursor of malignant lymphoproliferative disorders (multiple myeloma, Waldenstroem's disease, other non-Hodgkin's lymphoma, light chain (AL) - amyloidosis). However, many of these patients remain asymptomatic throughout their lives. Screening is performed by serum protein electrophoresis, immunofixation and determination of quantitative immunoglobulins and free light chains in serum. Currently, general population screening is not recommended. There are three subtypes with different rates and types of progression: IgM-MGUS, non-IgM-MGUS, and light-chain MGUS. The scope of further diagnostics and follow-up is based on the clinical findings and risk stratification (monoclonal protein in serum < or ≥ 15 g/l and normal or abnormal free light chain ratio in serum). If paraprotein-associated disease is detected, gammopathy is of clinical significance and should not be referred to as MGUS.

AB - Monoclonal gammopathy of unclear significance (MGUS) is detected at high frequency in a variety of disciplines as an incidental finding. MGUS can be associated with non-malignant diseases, but it also can be a precursor of malignant lymphoproliferative disorders (multiple myeloma, Waldenstroem's disease, other non-Hodgkin's lymphoma, light chain (AL) - amyloidosis). However, many of these patients remain asymptomatic throughout their lives. Screening is performed by serum protein electrophoresis, immunofixation and determination of quantitative immunoglobulins and free light chains in serum. Currently, general population screening is not recommended. There are three subtypes with different rates and types of progression: IgM-MGUS, non-IgM-MGUS, and light-chain MGUS. The scope of further diagnostics and follow-up is based on the clinical findings and risk stratification (monoclonal protein in serum < or ≥ 15 g/l and normal or abnormal free light chain ratio in serum). If paraprotein-associated disease is detected, gammopathy is of clinical significance and should not be referred to as MGUS.

KW - Disease Progression

KW - Humans

KW - Incidental Findings

KW - Monoclonal Gammopathy of Undetermined Significance/diagnosis

U2 - 10.1055/a-0832-3393

DO - 10.1055/a-0832-3393

M3 - SCORING: Review

C2 - 31311049

VL - 144

SP - 982

EP - 989

JO - DEUT MED WOCHENSCHR

JF - DEUT MED WOCHENSCHR

SN - 0012-0472

IS - 14

ER -